Precision Neuroscience Stock

precisionneuro.ioHealthcare / BioTech & PharmaFounded: 2021

Precision Neuroscience is a biotechnology company which offers brain–computer interface technology to patients with neurological conditions. Their flagship product, the Layer 7 Cortical Interface, is designed to conform to the brain's surface without damaging tissue, striving to enable high-resolution neural recording. Precision Neuroscience aims to connect human and artificial intelligence by developing minimally invasive neural implants that seek to translate brain signals into digital commands. The company was founded by Benjamin Rapoport and Michael Mager in 2021 and is headquartered in New York, NY.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Precision Neuroscience, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Private Market Pricing DetailsValuation & Financings

Precision Neuroscience Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Precision Neuroscience Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
Funding Round Details are not yet available for this company.

Precision Neuroscience investors also invested in these private companies

Leadership & Board

Leadership

Michael Mager
Chief Executive Officer and Co-Founder
Demetrios Papageorgiou
Co-Founder and SVP of Engineering

Precision Neuroscience stock FAQs

plusminus

Can you buy Precision Neuroscience stock?

As Precision Neuroscience is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Precision Neuroscience, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Precision Neuroscience stock?

To invest in a private company like Precision Neuroscience through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Precision Neuroscience stock?

Yes, you may sell the Precision Neuroscience stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Precision Neuroscience stock?

If you hold private company shares of Precision Neuroscience – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Precision Neuroscience on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Precision Neuroscience a public company?

No, Precision Neuroscience is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Precision Neuroscience’s stock price?

Precision Neuroscience is a privately held company and therefore does not have a public stock price. However, you may access Precision Neuroscience private market stock price with Forge Data.
plusminus

What is Precision Neuroscience’s stock ticker symbol?

Precision Neuroscience does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Precision Neuroscience’s news and media highlights

Precision Neuroscience recently closed a $93 million funding round, the brain–computer interface (BCI) developer said in a recent financial disclosure. New York City–based Precision Neuroscience said in the Securities and Exchange Commission filing that it hoped to raise up to $150 million in this latest round, and that 21 unidentified investors took part.
Neuralink rival, Precision Neuroscience, has shattered the world record by implanting over 4,096 electrodes in a human brain. The brain-computer interface company surpassed the previous record of 2,048 set last year. The higher number of electrodes allows more data to be transmitted to and from the brain, impacting the interface system’s capabilities.
Precision Neuroscience announced that it launched new clinical study sites at Mount Sinai Health System and the University of Pennsylvania. The company says the studies represent “a major step forward” as it aims to understand how the brain controls movement. It hopes to utilize the sites to advance its brain-computer interface (BCI) technology for people with neurological disorders.
Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine). These pioneering studies represent a major step forward in understanding how the brain controls movement and align closely with Precision’s commitment to transforming the lives of patients with neurological disorders.
Updated on: Nov 16, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.